StudyFinder

A Randomized Phase III Trial of Intravesical BCG VeRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

Recruiting

We want to see if we can lower the chance of bladder cancer growing or spreading by using a type of chemotherapy instilled in the bladder, Gemcitabine and Docetaxel. The usual approach for patients who are not in a study is treatment with Transurethral surgery of bladder tumor (TURBT) followed by instillations of Bacillus Calmette-Guerin (BCG) immunotherapy into the bladder via a catheter.

I'm interested

Male or Female
18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• at least 18 years old
• diagnosis of confirmed high-grade non-muscle invasive urothelial carcinoma of the bladder
• have not received prior intravesical therapy for bladder cancer
• capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:

• must not have any prior or current history of muscle-invasive, locally advanced unresectable, or metastatic urothelial cancer
• women who are pregnant or breast feeding

Drug: Bacillus Calmette Guerin, Drug: Docetaxel, Drug: Gemcitabine

Cancer

bladder cancer, Clinics and Surgery Center (CSC), urothelial Cancer

Mary Jo Hadler - hadle010@umn.edu
Hamed Ahmadi
PHASE3
STUDY00021094
See this study on ClinicalTrials.gov

Back